In a Q&A, Rob Besse shares his thoughts on making the leap from his family’s business to consulting, what manufacturers need to know before commercialization planning, and industry trends worth watching.

When manufacturers are planning the launch of a Buy-and-Bill product, there are certain steps that are imperative to include in the launch strategy and development of support services.

Determining if your HUB should be insourced, outsourced, or a hybrid of those two options is a big decision. And finding the right answer can determine the future success of your patient access program.

Before establishing an Expanded Access Program, it’s vital for manufacturers to align internally around several crucial program decisions. These five are key.

With no roadmap for Cell and Gene Therapy, it can be overwhelming to try to stay on top of all the moving parts. This overview of 4 key CGT topics will keep you up to date.